Abiopharma

🔍 Feeley Kevin (Executive)

Company: GeneDx Holdings Corp. (WGS)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Acquired 2,462 shares of Class A Common Stock (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 23,122.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,280 shares of Class A Common Stock at $86.754 per share (Direct)
  Date: 2026-03-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 21,842.00 | transaction_form_type: 4 | Footnotes: F2, F3, F4
• Sold 2,462 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 7,387.00 | transaction_form_type: 4 | Footnotes: F1, F5, F5

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
• F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.75 to $87.1136 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: Following the reported sale undertaken to satisfy tax withholding liabilities, in addition to the 21,842 shares of Class A Common Stock beneficially owned by the Reporting Person, the Reporting Person beneficially owned RSUs representing contingent rights to receive up to an aggregate of 120,435 shares of Class A Common Stock and options to purchase up to an aggregate of 25,906 shares of Class A Common Stock, which RSUs and options vest according to their respective terms.
• F5: 6.25% of the total award vested or vests quarterly, subject to the Reporting Person's continued service to the Issuer on each vesting date, and with the first tranche vested on March 9, 2023. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.